The APOBEC3B (A3B) somatic mutation signature (C>T point mutations at TC dinucleotides) is widespread in human cancers, but stratification of tumors based on A3B gene expression shows weak positive correlation with hypermutation. Further stratification with factors that increase the availability of ssDNA, the preferred substrate for A3B, will likely enhance this correlation and increase our understanding of the mechanisms behind this most pervasive mutational signature in human cancers. Alterations at the FHIT gene locus occur early in cancer initiation, leading to reduction or complete loss of Fhit protein expression in over 50% of cancers. Fhit loss causes replication stress and genome instability in cells without cell cycle arrest or apoptosis, allowing cells to accumulate DNA damage with each subsequent cell division. Thus, Fhit negative cells harbor increased availability of A3B target ssDNA, leading to our proposal that Fhit loss creates optimal A3B substrates that facilitate A3B-mediated mutagenesis. This research highlight summarizes our recent findings concerning the cooperation of Fhit loss-induced DNA damage and A3B overexpression. Briefly, DNA from FHIT deficient lung adenocarcinomas that also show high A3B expression exhibit the highest frequency of total mutations and A3B signature point mutations. In vitro, these mutations could be rescued by inhibiting the replication stress caused by Fhit loss. We also consider the role of Fhit loss itself in mutagenesis and what other enzymes may exploit Fhit loss-induced genome instability to increase mutagenesis. The recent advances in our understanding of A3B and Fhit loss-induced mutagenesis are applicable to the most common types of human cancers and involve events that occur at the very onset of cancer initiation.
DNA damage and mutations underlie cancer initiation and development [1] . Thus, defining the causative processes of these mutations is imperative to improving strategies for preventing initiation or progression of the disease. Mutations are found in both oncogenes and tumor suppressor genes in malignant tumors, with varying mutation frequencies and patterns among cancers originating in various organs. These patterns provide clues to the molecular mechanisms leading to the mutation spectrum, different mutagens leaving behind particular footprints. Mutations can occur due to endogenous or exogenous exposures. Exogenous sources of mutation are those that come from the environment, and several exogenous sources of mutations have been discovered, such as UV light, causing pyrimidine dimers, and smoking carcinogens causing C>A point mutations [2] . Thus, the mutation pattern for skin cancer is very different from the pattern in lung cancer. Endogenous sources of mutations have been more complicated to uncover. Some hereditary sources have been identified, such as defects in cellular responses to DNA damage, which allow for mutations to occur as a result of faulty repair mechanisms [3] . Active endogenous sources of DNA damage, such as reactive oxygen species and anaerobic conditions, have also been defined but have not thus far been confirmed as inducers of major mutation signatures observed in cancers [4] . Massive genome and exome sequencing endeavors have expanded the numbers of tumor sequences available for study and the resulting data allow identification of the different mutation patterns that typify various cancer types [5] . As a result, new candidate cancer mutagens are being identified.
One of the most widely observed mutation patterns observed in cancers is an abundance of C>T mutations in a TC dinucleotide sequence context (mutated base underlined) [6] . This pattern has been confirmed in breast, head and neck, cervix, bladder, lung adenocarcinoma, and lung squamous cell carcinoma and has been attributed to activity of members of the APOBEC family of enzymes. The human APOBEC family includes 11 members: Apolipoprotein B mRNA Editing enzyme, Catalytic subunit 1 (APOBEC1) on chromosome 6, APOBEC2 on chromosome 12, APOBEC3A, B, C, D, F, G, H on chromosome 22, APOBEC4 on chromosome 1, and Activation Induced Cytosine Deaminase (AID) on chromosome 6 [7] . Canonically, these enzymes function to defend against viral pathogens, including retroviruses, HIV, hepatitis viruses, and papillomaviruses, by deaminating cytosine bases in ssDNA intermediates of viral replication. They have also been shown to inhibit retrotransposition of L1 and Alu elements in human cells. APOBEC-mediated deamination converts cytosine bases to uracil, which base pairs with adenine during replication, leading to thymidine incorporation at the site of deamination during the following round of replication, and thus the C>T transitions ( Figure 1 ).
Burns et al. [8] were the first to confirm APOBEC activity in cancer and identified APOBEC3B (A3B) as the responsible family enzyme. When they examined APOBEC family mRNA species in human breast cancer tissues and cell lines, only A3B was up-regulated relative to the mRNAs of matched normal tissues. A3B is also the only APOBEC protein family member that constitutively localizes to the cell nucleus where the mutations would be occurring. Burns et al. also showed that A3B induction in cell lines increases the steady-state levels of genomic uracil and the in vitro frequency of C>T mutations in TP53 DNA. In examining breast tumor data sets, A3B expression levels correlated positively with both overall and C>T mutation loads in a TC specific context. The discovery of A3B as an endogenous source of mutations in cancers is ground-breaking for a number of reasons. First, it reveals a possible therapeutic target for common forms of cancer. This approach is particularly appealing, because normal cells show very little expression of A3B [8] . Thus, the inhibition of this enzyme would be specific for cancer cells, sparing normal cells. Furthermore, A3B is a non-essential enzyme; so inhibiting A3B activity will not affect most normal cells that may have slight expression [9] . Manipulation of A3B activity in cancer cells opens another potential avenue for cancer treatment. Instead The resulting replication stress provides ssDNA template for A3B deamination of cytosine bases to uracil. Due to decreased TTP pools, as a consequence of Fhit loss and associated replication stress, Fhit loss may also lead to increased genomic uracil residues independent of A3B deamination, as denoted by "?" in the figure. Genomic uracil lesions can be repaired via BER in an error-free manner; however they can also lead to various mutagenic events. DNA synthesis over uracil bases results in C>T transitions within two rounds of replication (A). U/G mispairs can also be recognized by mismatch repair machinery, causing increased DNA resection and mutations both at the site of genomic uracil and at nearby residues (B). A third possible outcome is uracil excision from the DNA by uracil DNA glycoslyase (UNG), resulting in abasic sites (C). Translesion synthesis over abasic sites causes C>T or C>G mutations depending on the active polymerase, which adds either A or G opposite abasic sites. Uracil excision could also result in DNA nicking, leading to single or double strand breaks if nicks occur in close proximity on opposite strands or as a result of replication machinery encounters with nicked DNA. These breaks then allow for mutagenic recombination events. Model partially adapted from Burns and colleagues [7] .
of inhibiting the deamination activity, it may also be advantageous to exacerbate the DNA damage caused by A3B activity, via modulation of the DNA damage response and repair pathways, to cause lethal A3B-mediated damage to cancer cells. Synthetic lethality such as this is a common approach to treating BRCA1/2-mutant cancers with PARP inhibitors [10] . These findings concerning A3B also suggest that, in some cases, genome hypermutation may not take as long to develop as was once thought, because A3B specifically targets ssDNA and can mutate many bases in ssDNA at once. Although simultaneous hypermutation has not been shown in cancer, APOBEC enzymes can cause multiple clustered and strand coordinated mutations in response to DNA break induction and repair of DNA mismatches [11] . Perhaps the reason this type of hypermutation is not found in normal tissues is that it would cause cell cycle arrest or apoptosis in cells with stable genomes, since such a heavy DNA damage burden would activate one or more DDR checkpoints, such as the ATR/Chk1 or ATM/Chk2 pathways [12] , as can occur with oncogene activation. Oncogenes can cause massive DNA damage in cells, and in normal, genome stable cells this DNA damage results in apoptosis or cellular senescence [13] . On the other hand, cells with prior loss of genome caretaker protein function continue to divide in the face of activated oncogene expression, allowing for downstream global genome instability and cellular transformation. In order for the DNA damage caused by A3B-induced deamination to be tolerated by cells long enough to be further processed into C>T mutations, there must already be some level of underlying genome instability present in the cells that allows for checkpoint evasion.
Our lab has described a condition that supplies this required underlying genome instability. Loss of fragile histidine triad protein (Fhit) function causes mild genome instability without checkpoint activation [14] [15] [16] . Fhit negative cells proliferate as well as, or better than, Fhit positive cells, though they exhibit increased dsDNA breaks and γH2AX and 53BP1 nuclear foci, markers of DNA damage [14] . Fhit has been known for many years as a tumor suppressor protein exhibiting loss or reduced expression in over 50% of human cancers, including common cancers such as breast and lung cancer [17] [18] [19] [20] . As a genome caretaker, Fhit positively regulates expression of thymidine kinase 1 (TK1), a protein necessary for sufficient thymidine triphosphate (TTP) pool synthesis [14] . Insufficient TK1 expression was shown to cause a nucleotide imbalance in Fhit-deficient cells, leading to replication fork stalling, collapse, and DNA breaks without checkpoint activation and cell cycle arrest. Further studies showed that this replication stress provided an environment of ongoing DNA damage that leads to increased chromosomal instability in cells from Fhit knockout mice, including chromosome breaks, aneuploidy, and increased point mutations [16] . Loss of Fhit also increases the appearance of fragile sites, genomic loci that form gaps and/or breaks in response to mild replication stress [21] . This genome caretaker function provided fresh avenues of research into Fhit biological function and suggested questions concerning DNA damage-associated proteins that might act on regions of Fhit-loss-associated DNA damage to cause the chromosome breaks and point mutations observed in Fhit knockout mouse cells.
While considering these questions, we noted with great interest the reports of involvement of APOBEC enzymes in hypermutation in cancer cells and cancers. The first indication for us that there might be a connection between Fhit loss-associated DNA damage and APOBEC-associated mutation activity was that many of the types of cancers exhibiting the APOBEC mutation signature were also cancers known to very frequently show reduction or complete loss of Fhit expression. Furthermore, the A3B enzyme acts on ssDNA. Thus, cooperating factors that increase the availability of this substrate could facilitate A3B-mediated mutagenesis. Indeed, Roberts et al. stated that "Once a mutagen is present (APOBEC in cancers), the limiting factor in cluster mutation formation seems to be the formation of ssDNA, where the length of the ssDNA region and the time it persists are the parameters determining the cluster's mutation density and length" [22] . We therefore hypothesized that, because of ongoing replication stress and DNA damage, Fhit loss creates optimum A3B substrates and Fhit-deficient tumor DNA would be more sensitive to A3B hypermutation.
To test this hypothesis we examined gene expression and somatic mutation datasets for lung adenocarcinoma, a typically Fhit-deficient cancer that exhibits the A3B signature [23] . Using The Cancer Genome Atlas (TCGA) gene expression datasets, we were able to stratify tumor DNA samples by both FHIT and A3B expression. We found that tumor samples that were both FHIT-deficient and high in A3B expression exhibited the highest frequency of mutations with the APOBEC signature. Tumors with normal FHIT expression level appeared to be resistant to the increased A3B activity in cancers; while FHIT-deficient cancers showed a step-wise increase in mutations in response to increasing A3B expression, A3B expression had no effect on mutation frequency in FHIT-normal samples. To demonstrate that the increase in mutations in A3B-high/FHIT-deficient tumor DNAs resulted from A3B activity on DNA substrates created by Fhit loss, we used an in vitro nested PCR approach to evaluate C>T mutation frequency in a portion of the TP53 gene under various expression conditions: A3B-low (uninduced)/Fhit-normal, A3B-high (induced)/Fhit-normal, and A3B-high (induced)/ Fhit-low (silenced) [23] . The PCR products were cloned and DNAs of individual clones were sequenced. A3B-high/Fhit-low clones showed the highest frequency of C>T mutations, an increase from 0.47 mutations/kb in A3B-high/Fhit-normal clones to 0.85/kb in A3B-high/Fhit-low clones, representing 378 additional A3B-mediated mutations/Mb in Fhit-low cells. To confirm that, mechanistically, Fhit loss-induced dsDNA breaks were responsible for the increased incidence of C>T mutations, we supplemented A3B-high/Fhit-low cells with 10 μM thymidine. This concentration of thymidine had previously been shown to rescue the cells from Fhit loss-induced replication stress and DNA damage [14] . Thymidine supplementation reduced the percentage of A3B-high/Fhit-low clones with C>T mutations to 0.38 mutations per kb, fewer than for A3B-high/Fhit-normal clones. These in vitro experiments confirmed the correlations observed for the TCGA data of the lung cancer cohort and support the hypothesis that Fhit loss and A3B overexpression cooperate to cause hypermutation that could facilitate cancer progression.
Our study suggests that reduction or loss of Fhit function can be a necessary precondition for the formation of the APOBEC mutational signature. A possible model for this is as follows: Loss of Fhit caretaker function causes spontaneous replication stress, generating an environment of ongoing DNA damage and ssDNA; upon A3B over-expression, cytidine nucleotides within these areas of DNA damage would be deaminated by A3B, leading to increased genomic uracil. Removal of genomic uracil has been shown to produce clusters of C>T mutations after subsequent rounds of DNA replication. This model for hypermutation due to synergism of Fhit loss and A3B activation is likely to apply to multiple types of cancer and suggests that it will be useful to stratify cancer cohorts by both FHIT and A3B expression to more accurately predict which cancers are most susceptible to A3B-induced hypermutation and may in future be targets for inhibition of A3B activity.
A pressing question that remains in the wake of these recent discoveries is how A3B becomes up-regulated in cancer. It has been determined that this activation is not caused by gene amplification, chromosome translocation, or promoter mutations [8] . A tempting current hypothesis, because of the known biological function of APOBEC family enzymes, is that viral infection could cause activation of A3B in normal cells. This hypothesis is supported by the fact that viral infection is implicated in the initiation of numerous cancers that exhibit the A3B signature, such as human papillomavirus (HPV)-driven cervical and head and neck cancers. Henderson et al. [24] have shown that A3B up-regulation is correlated with HPV-positive status in a cohort of head and neck cancers. It is possible that in this case A3B activity is a double-edged sword that fights the infection, but also gains access to and acts upon cellular genomic DNA. This suggests another question: when does A3B up-regulation occur? Viral infection can occur at any time, in healthy cells, transforming cells, or in mature cancer cells. When would viral up-regulation of A3B have a large impact on cells? One would expect that it would make a difference at any point as long as there was underlying genomic instability in the cells to allow for propagation of hypermutation, as discussed above. One study has demonstrated that in smoking-related lung cancer, carcinogen-induced mutations decreased during tumor progression and A3B-associated mutations increased over time [25] . This suggests that A3B up-regulation may be a later event in this type of cancer.
Aside from our investigation regarding the Fhit-A3B connection, our lab is also interested is what other enzymes may act on Fhit loss-damaged DNA. Loss of Fhit genome caretaker function causes ongoing replication stress, and A3B is not the only enzyme that can act upon this type of damaged DNA. Aberrant activity of various DNA polymerases and repair proteins could also cause mutations and chromosomal aberrations. Due to the mechanism underlying the DNA damage caused by Fhit loss, there are additional possibilities. Loss of Fhit causes a decrease in the TTP pools available for DNA replication. Perhaps in this case uracils are introduced into the nascent DNA in place of the scarce thymidine triphosphate. If this occurs, Fhit loss itself could cause an increase in genomic uracil, independent of A3B activity. Genomic uracils have been shown to lead to various point mutations. As discussed in this article, replication across these uracils results in C>T mutations. Uracils can also be excised from the DNA by uracil DNA glycosylase, resulting in abasic sites [7] . Translation synthesis over abasic sites has been shown to cause both C>G and C>T mutations. Furthermore, uracil excision can lead to DNA breakage, resulting in recombination events [7] . When repaired in an error-free manner, genomic uracils are dealt with by a base excision repair (BER) pathway. This pathway requires minimal DNA resection. However, one study has shown that occasionally BER is "hijacked" by mismatch repair machinery (MMR) and much more DNA resection is required [26] . In this study, Chen et al. deliberately introduced a number of mutations (that are normally repaired by BER) into cells and observed that the mutations were repaired, but the number of mutations in neighboring bases increased significantly. When the researchers silenced MMR proteins, these neighboring mutations were decreased [26] . This work suggests that, if Fhit loss causes aberrant genomic uracil incorporation, repair-associated mutagenesis may be another characteristic of Fhit-deficient cancers.
Mutations associated with DNA replication, such as those caused by Fhit loss, are repaired by two pathways, polymerase proofreading and mismatch repair (MMR). Thus, tumors with mutations in polymerases and/or MMR proteins would be more susceptible to Fhit loss-induced mutagenesis. In this sense, Fhit loss is a first "hit" in mutagenesis with a second hit in a proofreading or repair-associated gene. A recent report showed that "combined hereditary and somatic mutations of replication error repair genes results in rapid onset of hypermutated cancers" [27] . This study showed that brain tumors from patients with both inherited biallelic mismatch repair deficiency (bMMRD) and early somatic mutations in DNA polymerase ε or δ had an excess of mutations reaching 20,000 exome mutations [27] . Tumors with bMMRD alone displayed lower numbers of mutations, average 7,911 mutations. Mismatch repair defects are normally associated with microsatellite instability (MSI). Interestingly, tumors devoid of MMR activity but harboring polymerase mutations were microsatellite stable (MSS), indicating that polymerase defects cooperate with MMR defects to change the genetic landscape of the tumor DNA and shift the mutation patterns [27] .
These findings intrigued us, as Fhit loss had previously been linked to tumor types known to be associated with MMR deficiency-sebaceous gland cancers such as occur in Muir-Torre syndrome, an autosomal dominant, Lynch-syndrome associated condition [28] . Mutations in MMR proteins, commonly MSH2 or MLH1, lead to MSI in these tumors. FHIT inactivation also causes development of Muir-Torre-like sebaceous gland tumors but the FHIT loss-driven sebaceous tumors were microsatellite stable [29] . These data suggested that the somatic loss of the FHIT gene, associated with microsatellite stability, can lead to development of sebaceous tumors, similar to the MSI-associated Muir-Torre syndrome sebaceous tumors. The Fhit-sebaceous tumor connection observed in Fhit knockout mice was strikingly confirmed by studies of sebaceous cancers in humans, carried out over several years by investigators in Germany examining eye-associated sebaceous cancers, and culminating in the finding of BRCA1/2 and p53 mutations in Fhit-negative, microsatellite stable sebaceous gland cancers [30, 31] . These investigators suggested that Fhit-deficient sebaceous cancers exhibit impaired homologous recombination repair. In light of the new data concerning the ability of combined bMMRD/polymerase mutations in changing the microsatellite status and mutations spectrum of brain tumors, perhaps a similar phenomenon occurs in FHIT deficiency; FHIT loss may cooperate with polymerase defects to cause a unique pathway to initiation of the sebaceous gland cancers, independent of MMR deficiency and MSI.
How Fhit and polymerase activities could be linked is unknown. However, a recent study revealed a novel enzymatic function for Fhit [32] . In this study Fhit was shown to be a scavenger-decapping enzyme involved in 5' mRNA cap structure (m7GpppN) degradation. The 5' mRNA cap plays a major role in controlling gene regulation at the post-transcriptional level. During translation, the 5' mRNA cap associates with the eIF4E complex, playing a critical role in translation initiation [32] . Following translation, m7GpppN (free cap dinucleotides) are generated during 3'-> 5' mRNA degradation. Canonically, the Scavenger-Decapping Enzyme (Dcps) hydrolyzes these free cap dinucleotides to form m7GMP [32] . The Séraphin and Taverniti study showed that Fhit also cleaves m7GpppN structures to produce both m7GDP and m7GMP. Dcps and Fhit are both members of the histidine triad (HIT) superfamily of proteins, which contain conserved histidine residues and hydrolyze nucleotide derivatives. In this study Fhit loss caused an aberrant accumulation of m7GpppN cap structures. High levels of m7GpppN inhibit translation and polysome formation by competitively binding eIF4E [32] . Thus loss of Fhit and subsequent free cap dinucleotide accumulation could lead to deregulation of particularly susceptible mRNAs, leading to down-regulation of specific proteins, including TK1, in specific tissues. Perhaps mRNAs affected by this phenomenon, such as DNA polymerase mRNAs, could be involved in Fhit loss-mediated mutagenesis.
The recent advances in our understanding of A3B and Fhit loss-induced mutagenesis stand out because these mechanisms are active in the most common types of human cancers. Furthermore, these discoveries involve events that occur at the onset of cancer initiation. Alterations at the FHIT locus are among the earliest events in the preneoplastic process [18, 33] . Thus, targeting Fhit loss-induced DNA damage through prevention strategies, or by a synthetic lethality strategy to eliminate Fhit-deficient cells, would allow an opportunity not only to treat mature cancers, but possibly to prevent cancer progression from the preneoplastic state. It is not yet known when A3B activation occurs, but at any stage of cancer initiation or progression, targeting A3B activity offers a cancer-specific avenue for therapy. This is an exceptional opportunity to use these important discoveries to improve current cancer therapies by developing strategies that may better target heterogeneous tumor cell populations and improve patient care.
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